| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
167,290,000 |
| Market
Cap: |
182.35(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6061 - $2.49 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile X4 Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of therapeutics for the treatment of rare diseases. Co.'s primary product candidate is mavorixafor, a small molecule chemokine receptor type 4 (CXCR4) antagonist that inhibits receptor binding by CXCL12, the cognate ligand of CXCR4. Co. is conducting clinical trials of mavorixafor: for the treatment of Warts, Hypogammaglobulinemia, Infections, and Myelokathexis syndrome, a rare primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene; and in people with chronic neutropenia and Waldenstrom's macroglobulinemia, a rare B-cell lymphoproliferative disorder.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
25,000 |
25,000 |
| Total Buy Value |
$0 |
$0 |
$29,875 |
$29,875 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
185,708 |
185,708 |
353,799 |
624,831 |
| Total Sell Value |
$170,713 |
$170,713 |
$383,960 |
$557,665 |
| Total People Sold |
4 |
4 |
5 |
6 |
| Total Sell Transactions |
8 |
8 |
19 |
42 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Skerlj Renato |
Chief Scientific OfficerOffice |
• – – |
2020-06-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
30,410 |
|
-21% |
|
| Ragan Paula |
President and CEO |
• – – |
2020-06-03 |
4 |
AS |
$8.88 |
$86,198 |
D/D |
(9,707) |
213,712 |
|
-24% |
|
| Ragan Paula |
President and CEO |
• – – |
2020-06-02 |
4 |
AS |
$8.65 |
$20,760 |
D/D |
(2,400) |
223,419 |
|
-19% |
|
| Ragan Paula |
President and CEO |
• – – |
2020-06-01 |
4 |
AS |
$8.63 |
$36,893 |
D/D |
(4,275) |
225,819 |
|
-19% |
|
| Ragan Paula |
President and CEO |
• – – |
2020-05-04 |
4 |
AS |
$8.92 |
$21,408 |
D/D |
(2,400) |
230,094 |
|
-18% |
|
| Ragan Paula |
President and CEO |
• – – |
2020-04-02 |
4 |
AS |
$8.40 |
$20,160 |
D/D |
(2,400) |
232,494 |
|
-3% |
|
| Ragan Paula |
President and CEO |
• – – |
2020-03-02 |
4 |
AS |
$10.64 |
$25,536 |
D/D |
(2,400) |
234,894 |
|
-24% |
|
| Mostafa Adam S. |
CFO and Treasurer |
• – – |
2019-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
10,564 |
10,564 |
|
- |
|
| Ragan Paula |
President and CEO |
• • – |
2019-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
55,928 |
237,294 |
|
- |
|
| Ragan Paula |
President and CEO |
• • – |
2019-03-13 |
4 |
A |
$0.00 |
$0 |
D/D |
181,366 |
181,366 |
|
- |
|
| Gray Michael |
President, CEO and CFO |
• • – |
2018-11-27 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
250,000 |
|
- |
|
| Alphabet Inc. |
10% Owner |
– – • |
2017-11-20 |
4 |
A |
$0.00 |
$0 |
I/I |
451,362 |
451,362 |
|
- |
|
| Nessi Claudio |
Director |
– • – |
2017-11-20 |
4 |
B |
$10.00 |
$3,000,000 |
I/I |
300,000 |
867,639 |
2.1 |
- |
|
| Nessi Claudio |
Director |
– • – |
2017-11-20 |
4 |
A |
$0.00 |
$0 |
I/I |
567,639 |
567,639 |
|
- |
|
| Muhlenbeck Frank |
10% Owner |
– – • |
2017-11-20 |
4 |
B |
$10.00 |
$200,000 |
D/D |
20,000 |
370,454 |
2.45 |
- |
|
| Muhlenbeck Frank |
10% Owner |
– – • |
2017-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
350,454 |
350,454 |
|
- |
|
| Flint Jonathan A |
10% Owner |
– – • |
2017-11-20 |
4 |
B |
$10.00 |
$5,000,000 |
I/I |
500,000 |
18,031 |
1.5 |
- |
|
| Flint Jonathan A |
10% Owner |
– – • |
2017-11-20 |
4 |
A |
$0.00 |
$0 |
I/I |
1,368,957 |
13,206 |
|
- |
|
| Isaly Samuel D |
10% Owner |
– – • |
2017-11-20 |
4 |
A |
$0.00 |
$5,000,000 |
I/I |
1,868,966 |
1,868,966 |
|
- |
|
| Ross Michael Jay |
Director |
– • • |
2017-11-20 |
4 |
B |
$10.00 |
$5,000,000 |
I/I |
500,000 |
1,868,961 |
2.25 |
- |
|
| Ross Michael Jay |
Director |
– • • |
2017-11-20 |
4 |
A |
$0.00 |
$0 |
I/I |
1,368,961 |
1,368,961 |
|
- |
|
| Bill & Melinda Gates Foundation |
|
• • • |
2017-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
722,179 |
722,179 |
|
- |
|
| Mcguire Terrance |
Director |
– • • |
2017-11-20 |
4 |
B |
$10.00 |
$5,000,000 |
I/I |
500,000 |
18,031 |
2.25 |
- |
|
| Mcguire Terrance |
Director |
– • • |
2017-11-20 |
4 |
A |
$0.00 |
$0 |
I/I |
1,368,957 |
13,206 |
|
- |
|
| Gerngross Tillman U. |
Director |
– • – |
2017-11-20 |
4 |
B |
$10.00 |
$2,000,000 |
D/D |
200,000 |
392,821 |
2.39 |
- |
|
160 Records found
|
|
Page 6 of 7 |
|
|
0.11 (9.17%) 
